Table 1.

Clinical Characteristics

	Age	Dx	Sex	Prior Chemotherapy	Regimens Prior to SCT	CD 34 × 106/kg	Planned aATC Dose ×109	ActualaATC Dose ×109	Status at SCT	Status at 90 days	C-IT*	Survival (days) (D†/A‡)
1	54	DLBCL	M	RCHOP X4, RICE X2	2	2.6	20	18.4	PRF	PD 56 days	N	107 (D)
2	53	DLBCL	F	RCHOP X8, RICE X2	2	8.4	20	17.15	PRF	PD 30 days	Y	111 (D)
3	67	DLBCL	F	RCHOP X6, RICE X2	2	7.1	40	38.64	PR	CR	Y	1294 (A)
4	55	FCL	F	RCHOP X6, RICE X2	2	3.2	40	37.44	CR2	PD 60 days	Y	126 (D)
5	61	DLBCL	M	R-CHOP X8, RICE X2	2	6.1	40	37.28	CR2	PD 52 days	Y	112 (D)
6	59	DLBCL	M	RCHOP X6, RCEOP X4	2	6.0	60	60	CR2	CR	Y	984 (A)
7	56	DLBCL	F	RCHOP X8, RICE X2	2	2.6	60	45	CR2	PR	N§	987 (A)
8	67	DLBCL	M	RCHOP X6	1	12.3	60	61.6	CR1U	CR	Y	914 (A)
9	47	DLBCL	M	R X4, RCHOP X6	2	4	60	48.92	PR1	PD 67 days	Y	184 (D)
10	59	DLBCL	F	RCHOP X8, RICE X4	2	9.5	80	82	CR2U	CR	Y	781 (A)
11	46	DLBCL	M	RCHOP X8, RICE X2	2	6.0	80	67.64	CR2	CR	Y	718 (A)
12	61	DLBCL	M	RCVP X2, RCHOP X6	2	2.5	80	78.04	PR	CR	Y	711 (A)

DLBCL indicates Diffuse large B cell lymphoma; FCL, Follicular lymphoma; R, rituximab; RCHOP, rituximab, cyclophosphamide, adriamycin, vincristine, and prednisone; RCVP, rituximab-cyclophosphamide, vincristine, and prednisone; RICE, rituximab, ifosphamide, carboplatin, and etoposide; CVAD, cyclophosphamide, vincristine, adriamycin, and dexamethasone; RCEOP, rituximab-cyclophosphamide, etoposide, vincristine, and prednisone; CR, clinical remission; PR, partial response; PRF, progressive refractory disease; PD, progressive disease.

^*C-IT: Immunotherapy completed yes (Y) or no (N).

^†Alive (A) or dead (D).

^‡Survival days after SCT.

^§Received 3 out of 4 infusions.